Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 1, 2006

PerkinElmer Secured Evotec’s HTS Division for $30.62M

  • PerkinElmer procured high-throughput screening company Evotec Technologies for approximately EUR23 million, or $30.62 million, in cash. The company expects to close the transaction in the first quarter of 2007.

    Through this acquisition, PerkinElmer will be able to provide Evotec Technologies’ high-content screening instruments and analysis software. “Our customers today require unique, flexible tools and platforms that produce better quality and biologically relevant data for mapping cellular events to new discoveries,” says Gregory L. Summe, chairman and CEO, PerkinElmer. “Evotec Technologies’ strong product portfolio combined with PerkinElmer’s global distribution capabilities, service, and support will help our customers speed target validation and lead optimization along the drug discovery pipeline.”

    Joern Aldag, CEO of parent company, Evotec says that this transaction permits Evotec to focus on its drug discovery and development business. “Together with the sale of certain technology assets of Evotec Technologies to Olympus earlier in the year, the combined divestments value Evotec Technologies at approximately EUR30 million. The cash proceeds will provide us with additional flexibility to progress and expand our Central Nervous System pipeline.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »